StockNews.com Downgrades Omnicell (NASDAQ:OMCL) to Hold

StockNews.com cut shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research report released on Wednesday.

A number of other brokerages have also weighed in on OMCL. Bank of America reaffirmed a “neutral” rating and set a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum upped their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company upped their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Finally, Barclays upped their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Price Performance

Shares of OMCL stock opened at $48.46 on Wednesday. The business’s fifty day moving average price is $44.41 and its 200 day moving average price is $37.75. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74. The firm has a market capitalization of $2.24 billion, a PE ratio of -124.25, a P/E/G ratio of 34.92 and a beta of 0.81.

Institutional Trading of Omnicell

Large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its stake in shares of Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the last quarter. CWM LLC boosted its stake in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after acquiring an additional 1,236 shares during the last quarter. 1620 Investment Advisors Inc. boosted its stake in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Omnicell during the second quarter valued at $104,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.